MX2009006873A - Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. - Google Patents

Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.

Info

Publication number
MX2009006873A
MX2009006873A MX2009006873A MX2009006873A MX2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A MX 2009006873 A MX2009006873 A MX 2009006873A
Authority
MX
Mexico
Prior art keywords
wet granulation
solid dose
disintegrant
formula
dosage form
Prior art date
Application number
MX2009006873A
Other languages
English (en)
Inventor
David Harris
Zhi Yun Wang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009006873A publication Critical patent/MX2009006873A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una forma de dosificación sólida de desintegración rápida que comprende un ingrediente farmacéutico activo, un desintegrador y un promotor de desintegración, cuya formulación se puede obtener mediante un procedimiento de granulación húmeda; en una modalidad ejemplificada, el agente farmacéutico activo es un antagonista del receptor de trombina, el desintegrador es croscarmelosa de sodio, y el promotor de desintegración es silicato de calcio; en algunas modalidades, el antagonista del receptor de trombina está representado por la fórmula: (ver fórmula) o su sal farmacéuticamente aceptable; también se describen métodos para tratar pacientes en riesgo de síndrome coronario agudo mediante la administración de dicha forma de dosificación sólida de desintegración rápida.
MX2009006873A 2006-12-22 2007-12-19 Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. MX2009006873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87160506P 2006-12-22 2006-12-22
PCT/US2007/025996 WO2008079260A2 (en) 2006-12-22 2007-12-19 Disintegration promoters in solid dose wet granulation formulations

Publications (1)

Publication Number Publication Date
MX2009006873A true MX2009006873A (es) 2009-07-03

Family

ID=39467196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006873A MX2009006873A (es) 2006-12-22 2007-12-19 Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.

Country Status (6)

Country Link
US (1) US20080194560A1 (es)
EP (1) EP2120879A2 (es)
JP (1) JP2010513516A (es)
CA (1) CA2673228A1 (es)
MX (1) MX2009006873A (es)
WO (1) WO2008079260A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
CN101465825B (zh) * 2008-12-31 2012-07-11 阿里巴巴集团控股有限公司 即时通信的方法、即时通信服务器、语音服务器及系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304773A (en) * 1980-06-26 1981-12-08 E. R. Squibb & Sons, Inc. Novel bendroflumethiazide formulations and method
FR2623810B2 (fr) * 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) * 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) * 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
KR100604742B1 (ko) * 2000-06-15 2006-07-26 쉐링 코포레이션 트롬빈 수용체 길항제
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US6521270B1 (en) * 2001-06-11 2003-02-18 The Procter & Gamble Company Compositions comprising nitrofurantoin and uva ursi
TWI324074B (en) * 2001-10-09 2010-05-01 Bristol Myers Squibb Co Flashmelt oral dosage formulation
EP1436298B1 (en) * 2001-10-18 2011-09-21 Schering Corporation Himbacine analogues as thrombin receptor antagonists
ATE494284T1 (de) * 2002-04-16 2011-01-15 Schering Corp Tricyclischer thrombinrezeptorantagonist
JP2004238348A (ja) * 2003-02-07 2004-08-26 Fuji Pharmaceutical Co Ltd 経口投与用イトラコナゾール製剤
DE10317816A1 (de) * 2003-04-16 2004-11-04 Claas Selbstfahrende Erntemaschinen Gmbh Feldhäcksler mit positionierbarer Fahrerkabine
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2009542677A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション トロンビン受容体拮抗薬の固形製剤
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist

Also Published As

Publication number Publication date
EP2120879A2 (en) 2009-11-25
CA2673228A1 (en) 2008-07-03
WO2008079260A3 (en) 2008-09-25
US20080194560A1 (en) 2008-08-14
WO2008079260A2 (en) 2008-07-03
JP2010513516A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
RU2016122609A (ru) Составы соединений азаиндола
CA2795804C (en) Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
EA200900264A1 (ru) Композиции флибансерина и способ их приготовления
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
CA2601955A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CR8047A (es) Procedimiento de tratamiento de la arterosclerosis, dislipidemias y afecciones relacionadas y composiciones farmaceuticas
JP2014533733A5 (es)
WO2009110005A3 (en) Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
BRPI0519398A2 (pt) compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
ES2923214T3 (es) Composición farmacéutica que comprende mesilato de lenvatinib
CA2671470A1 (en) Powder formulation for valganciclovir
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
MX2009003317A (es) Tabletas pediatricas de capecitabina.
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
NO20091644L (no) Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist
MX2012002681A (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
JP2016512234A (ja) 薬学的複合製剤
NZ591408A (en) Paracetamol and Calcium carbonate composition
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
WO2006134492A3 (en) Acarbose methods and formulations for treating chronic constipation
CA2529604A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
UA95274C2 (ru) Твердый фармацевтический препарат, содержащий ирбесартан, и способы его изготовления

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal